These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3892064)

  • 1. LHRH.
    Glode LM; Smith JA
    JAMA; 1985 Jul; 254(4):506-7. PubMed ID: 3892064
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Kerle D; Williams G; Ware H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 4. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostatic cancer: treatment with long-acting LHRH analogue.
    Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
    Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction and maintenance of castration by an LHRH analogue: D-Trp6 LHRH or decapeptyl.
    Fretin J; Demerle F; Jardin A
    Prog Clin Biol Res; 1987; 243A():245-7. PubMed ID: 2958855
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 10. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
    Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography.
    Kojima M; Watanabe H; Ohe H; Miyashita H; Inaba T
    Prostate; 1987; 10(1):11-7. PubMed ID: 3103113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
    Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

  • 15. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 20. The LHRH antagonist cetrorelix: a review.
    Reissmann T; Schally AV; Bouchard P; Riethmiiller H; Engel J
    Hum Reprod Update; 2000; 6(4):322-31. PubMed ID: 10972520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.